Rossari Biotech to launch Rs 500 cr initial public offering on Monday

Rossari has reduced the fresh issue component from Rs 150 crore to Rs 50 crore

IPO
The IPO also comprises a secondary share sale of 10.5 million shares by promoters
Sundar Sethuraman Mumbai
2 min read Last Updated : Jul 09 2020 | 12:45 AM IST
Rossari Biotech, a specialty chemicals company, will launch its Rs 500-crore initial public offering (IPO) on Monday, ending a four-month lull in the primary market. The last IPO to hit the domestic market was that of SBI Cards and Payment Services in early March. The Covid-19 pandemic and the economic lockdown have forced many companies to hold back their IPO plans despite regulatory clearances. Rossari had intended to launch its IPO in March only, but decided to postpone the plan.

The company on Wednesday conducted media and analyst meetings through the video-conferencing service Zoom.

Rossari has reduced the fresh issue component from Rs 150 crore to Rs 50 crore. It raised Rs 100 crore through a pre-IPO placement. The IPO also comprises of a secondary share sale of 10.5 million shares by promoters.

The price band for the IPO is Rs 423 to Rs 425 per share. At the top end, the IPO size works out to nearly Rs 500 crore and implies a post-IPO market cap of Rs 2,207 crore. 
Following the IPO, the promoter holding in the company will fall from 95.06 per cent to 72.7 per cent.

The IPO will close on Wednesday. Axis Capital and ICICI Securities are the investment banks handling the issue.

Rossari Biotech manufactures chemicals used in the FMCG, apparel, poultry and animal feed industries. For the year-ended March 2020, the company had reported net profit of Rs 65crore on revenues of nearly Rs 603 crore.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Specialty chemicalsbiotechIPO

Next Story